Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Basilea (SWX:BSLN) said ceftobiprole ( BAL5788) met the primary endpoint of non-inferiority vs.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury